NO TO HATTATSU
Online ISSN : 1884-7668
Print ISSN : 0029-0831
ISSN-L : 0029-0831
Non-Intravenous High-Dose Phenobarbital Therapy for Status Epilepticus Refractory to Continuous Infusion of Midazolam or Pentobarbital: Report of Three Cas
Akira SudohKenji SugaiTakeshi MiyamotoMasakazu MimakiMichio FukumizuShigeru HanaokaMasayuki Sasaki
Author information
JOURNAL FREE ACCESS

2002 Volume 34 Issue 1 Pages 23-29

Details
Abstract
The management of refractory status epilepticus (RSE) is crucial in preventing neurologic impairment.Although a variety of treatments for RSE including continuous infusion of midazolam (MDL) or pentobarbital (PTB) have been carried out, they are not always effective. Intravenous very-high-dose phenobarbital (PB) has been recommended as having many advantages in the United States, but is not available in Japan.
We treated 3 patients suffering from long term RSE with non-intravenous high-dose PB (NIHDPB). T h e i r seizures were not controlled by continuous infusion of MDL and/or PTB. PB was initially given intramuscularly or rectally and then orally. Within a few or ten days, seizures were completely controlled, and consiousness level g r a dually improved in all cases. The serum levels of PB at seizure control ranged from 50 to 58μg/ml. The epilepti form activities on EEG nearly disappeared in the absence of the burst suppression pattern. Hypotention and respiratory depression did not develop during NIHDPB. Elevated gamma-GTP levels with normal hepatic transaminases were seen in all cases, but it was not necessary to discontinue NIHDPB. NIHDPB may be one of the most effective and safe treatments in Japan for status epileptics refractory to continuous infusion of MDL or PTB.
Content from these authors
© Japanese Society of Child Neurology
Previous article Next article
feedback
Top